Welcome to our dedicated page for Evolus SEC filings (Ticker: EOLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Evolus's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Evolus's regulatory disclosures and financial reporting.
MOATAZEDI DAVID reported acquisition or exercise transactions in this Form 4 filing.
Evolus, Inc. director and officer David Moatazedi reported equity awards on February 17, 2026. He was granted 626,424 performance-based restricted stock units, where each unit can deliver up to 200% of a target share amount based on financial metrics and relative total shareholder return over a three-year period ending December 31, 2028. He also received 313,212 time-based restricted stock units and 457,541 stock options, each vesting in four equal annual installments starting on February 17, 2026, subject to continued service and potential acceleration in certain circumstances.
Malik Vikram reported acquisition or exercise transactions in this Form 4 filing.
Evolus, Inc. director Vikram Malik reported an equity award of 45,559 shares of common stock in the form of restricted stock units (RSUs). Each RSU represents the right to receive one share of Evolus common stock for no cash payment.
The RSUs will vest in full on the one year anniversary of February 17, 2026, as long as Malik remains in continuous service, with accelerated vesting possible in certain change-of-control or similar events. After this grant, Malik beneficially owns 321,109 shares of Evolus common stock.
Avelar Rui reported acquisition or exercise transactions in this Form 4 filing.
Evolus, Inc. reported that company officer Rui Avelar received new equity awards on February 17, 2026. Grants included 94,913 performance-based restricted stock units, 94,913 time-based restricted stock units payable in common stock, and stock options for 138,649 shares at no cost on grant.
The time-based RSUs and options vest in four equal annual installments starting February 17, 2026, subject to continued service and possible acceleration in certain circumstances. The performance-based units can deliver up to 200% of the granted PSUs based on financial metrics and relative total shareholder return over a three-year period ending December 31, 2028.
GILL DAVID N reported acquisition or exercise transactions in this Form 4 filing.
Evolus, Inc. director David N. Gill received a grant of 45,559 restricted stock units (RSUs) of common stock. The award was made at no cash cost per share and will vest in full on the one-year anniversary of February 17, 2026, if he remains in continuous service. Following this grant, Gill directly holds 86,887 shares or share-equivalent RSUs.
Evolus, Inc. received an updated ownership report from Caligan Partners LP and David Johnson showing they no longer beneficially own any of its common stock. The filing states each reporting person has 0 shares with sole or shared voting and dispositive power, representing 0.0% of the common stock class as of the reported date. The reporters also certify the securities were acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of Evolus.
Tang Capital Management and related entities reported beneficial ownership of Evolus, Inc. common stock totaling 1,245,692 shares, representing 1.92% of the outstanding class. These shares are held with shared, not sole, voting and dispositive power across several Tang-affiliated funds and entities.
The ownership is spread among Tang Capital Partners, Tang Capital Partners International, Tang Capital Partners III, and Tang Capital Partners IV, with Kevin Tang sharing voting and investment authority. The filing notes that the securities are not held for the purpose of changing or influencing control of Evolus.
Timothy P. Lynch reports beneficial ownership of 6,425,726 shares of Evolus, Inc. common stock, representing 9.9% of the class. This includes 4,705,009 shares over which he has sole voting and dispositive power and 1,720,717 shares with shared voting and dispositive power.
The ownership percentage is based on 64,819,784 shares of Evolus common stock outstanding as of October 31, 2025, as reported by the company. Lynch states that the securities were not acquired and are not held for the purpose of changing or influencing control of Evolus.
Evolus, Inc. filed a current report to disclose that it has issued a press release with preliminary, unaudited net revenue and other operational and financial data for the quarter and year ended December 31, 2025. The press release, dated January 9, 2026, is included as an exhibit to the report.
The company states that this information, including the exhibit, is being furnished rather than filed, which limits the legal exposure associated with these preliminary figures and keeps them separate from formal Securities Act and Exchange Act filings unless specifically incorporated by reference.
Evolus, Inc. reported Q3 2025 results with total net revenues of $68,967, up from $61,085 a year ago. Gross profit was $45,841, but operating expenses of $57,341 (including $1,443 in restructuring costs) led to a loss from operations of $11,500 and a net loss of $15,737, or $0.24 per share.
Cash and cash equivalents were $43,523 at quarter end, with net cash used in operating activities of $55,092 year-to-date. Long‑term debt on the balance sheet was $145,780, reflecting the May 2025 Amended and Restated Loan Agreement that provides up to $250,000 in senior secured term loans, including an initial $150,000 funded. Stockholders’ equity was a deficit of $28,760. The company launched Evolysse Form and Smooth in the U.S. in April 2025 and continues to commercialize Jeuveau across multiple markets. Shares outstanding were 64,819,784 as of October 31, 2025.
Evolus, Inc. (EOLS) furnished an 8-K announcing it issued a press release with financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1. As provided in General Instruction B.2, the information in Item 2.02 (including Exhibit 99.1) is furnished and not deemed “filed” under the Exchange Act, and will only be incorporated by reference if specifically stated in a future filing.